Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Current Oncology Reports
|
January 12, 2012
Survivin in solid tumors: rationale for development of inhibitors
David N Church, Denis C Talbot
Current Oncology Reports
|
August 31, 2012
In reply: response to Marioni
David N Church, Denis C Talbot
Immunotargets and Therapy
|
July 30, 2016
The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma
Sarah Ew Briggs, Paul Gozzard, Denis C Talbot
JAMA Oncology
|
November 29, 2016
Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors
Robert M J Purbrick, Olaoluwakitan A Osunkunle, Denis C Talbot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2010
What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions
Valerie Jenkins, Ivonne Solis-Trapala, Carolyn Langridge, et al.
Molecular Therapy. Nucleic Acids
|
January 25, 2013
Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors
Anna L Olsen, Joanne M Davies, Louise Medley, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
December 2, 2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Anna C Bibby, Selina Tsim, Nikolaos Kanellakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2003
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression
Jeremy P Braybrooke, Nicola C Levitt, Simon Joel, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 24, 2010
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma
William G Herrington, Denis C Talbot, Michael M Lahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2007
Phase II study of vinflunine in malignant pleural mesothelioma
Denis C Talbot, Jacques Margery, Gérard Dabouis, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Current Oncology Reports
|
January 12, 2012
Survivin in solid tumors: rationale for development of inhibitors
David N Church, Denis C Talbot
Current Oncology Reports
|
August 31, 2012
In reply: response to Marioni
David N Church, Denis C Talbot
Immunotargets and Therapy
|
July 30, 2016
The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma
Sarah Ew Briggs, Paul Gozzard, Denis C Talbot
JAMA Oncology
|
November 29, 2016
Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors
Robert M J Purbrick, Olaoluwakitan A Osunkunle, Denis C Talbot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2010
What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions
Valerie Jenkins, Ivonne Solis-Trapala, Carolyn Langridge, et al.
Molecular Therapy. Nucleic Acids
|
January 25, 2013
Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors
Anna L Olsen, Joanne M Davies, Louise Medley, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society
|
December 2, 2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Anna C Bibby, Selina Tsim, Nikolaos Kanellakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2003
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression
Jeremy P Braybrooke, Nicola C Levitt, Simon Joel, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 24, 2010
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma
William G Herrington, Denis C Talbot, Michael M Lahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2007
Phase II study of vinflunine in malignant pleural mesothelioma
Denis C Talbot, Jacques Margery, Gérard Dabouis, et al.
Page
of 3